
Institute of Science Tokyo and other biopharma developers select AGC Biologics for cell therapy development and manufacturing support, reflecting growing momentum in Japan’s cell and gene therapy sector.
YOKOHAMA, Japan, Nov. 17, 2026 – AGC Biologics announced that three biopharma developers, including the Institute of Science Tokyo, have selected its new Yokohama facility to provide cell therapy services. The projects cover process development, technology transfer and manufacturing support for preclinical and clinical programs, as Japan’s cell and gene therapy (CGT) sector continues to gain momentum.
Although interest in cell and gene therapy development is increasing in Japan, the availability of contract development and manufacturing organizations (CDMOs) with the required institutional knowledge, manufacturing capabilities, skilled personnel and international networks remains limited. AGC Biologics aims to support developers operating in a resource-constrained environment by providing specialized cell therapy services and access to its global capabilities.
AGC established its cell therapy services at the Yokohama site in July 2025, combining approximately 30 years of experience and manufacturing expertise from its Milan facility with more than a century of manufacturing excellence from the AGC Group in Japan. This combination positions the company to support the growing requirements of the cell and gene therapy industry.
The Yokohama facility will provide process transfer and manufacturing services for preclinical and clinical trials. Its technology capabilities include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, exosomes and CAR-T cell therapies, supporting developers with diverse research and manufacturing requirements.
Supporting Clinical Development of Virus-Specific T Cell Therapy
One of the programs supported by the Yokohama facility is led by the Institute of Science Tokyo. The research aims to advance third-party virus-specific T cell therapy toward clinical application for patients with treatment-resistant adenovirus infections following hematopoietic cell transplantation.
“Viral infections following hematopoietic cell transplantation represent a major clinical challenge in patients with compromised immune function and can lead to severe, potentially life-threatening complications,” said Takahiro Kamiya, M.D., Ph.D., Junior Associate Professor at the Institute of Science Tokyo Graduate School of Medical and Dental Sciences. “With support from the Japanese Agency for Medical Research and Development under its Research Program for Intractable Diseases, we are advancing the research and development of virus-specific T-cell therapy toward clinical implementation for refractory adenovirus infections following hematopoietic cell transplantation.”
AGC Biologics is supporting the program through process development and analytical method development activities at its Yokohama facility. These activities are intended to support future clinical implementation and manufacturing.
Global Coordination with AGC Biologics’ Milan Cell and Gene Center of Excellence
Another project involves transferring a customer program from AGC Biologics’ Milan facility to Yokohama, where further development and manufacturing activities will be conducted.
Through coordination across its international network, AGC Biologics provides development and manufacturing support tailored to customers’ changing project requirements and business environments.
“By combining technologies developed across our global network with AGC’s unique materials expertise, we provide globally aligned development support services to customers worldwide,” said Tadashi Murano, President of AGC Life Science Company. “Going forward, we will continue to provide integrated support from early-stage development through commercialization, helping accelerate our customers’ research and development activities.”
“AGC Biologics has accumulated extensive experience in the development and manufacturing of cell therapy products through its global operations,” said Takahiro Kamiya. “As we prepare for this collaboration, we have also been impressed by the strength of its research and development capabilities, its robust infrastructure, and the dedication and enthusiasm of its team.”
The development and manufacturing activities of AGC Biologics’ Cell and Gene Technologies Division have supported 18 commercial product approvals for its customers.
Japan’s Cell and Gene Therapy Sector Gains Momentum
Proactive government initiatives and regulatory changes have contributed to renewed interest and increased early-stage development activity in Japan’s cell and gene therapy sector. A recent analysis by Dark Horse Consulting and AGC Biologics examines the country’s expanding role in the global CGT industry.
“As Western biopharmaceuticals and investors increasingly turn their attention eastward, much of the spotlight has centered on China, driven by its scale, clinical speed and cost advantages,” said H. Deborah Chen and Kang Liu, authors of the report From Laboratory to Launchpad: Japan’s Cell and Gene Therapy Ecosystem Hits Its Stride. “Yet, Japan with its deep scientific expertise, expanding manufacturing infrastructure, and strong global accessibility represents both a growing market and a potential hub for CGT innovation across Asia that should not be overlooked.”
The report outlines the opportunities available to global CGT developers in Japan, along with important considerations for companies planning to establish a presence or conduct clinical trials in the country.
Frequently Asked Questions
Will the Yokohama cell therapy services be limited to products seeking approval from Japan’s PMDA, or will they also support products pursuing international regulatory approvals?
The Yokohama cell therapy services will not be limited to a single regulatory jurisdiction. Regulatory pathways will be determined according to customer requirements and the markets they intend to serve, including Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory authorities.
AGC Biologics’ unified global quality system provides consistent quality standards and regulatory support across its operations. The company has worked with regulatory agencies across four continents and has passed more than 100 regulatory inspections involving agencies including the FDA, EMA and PMDA.
What is the SAKIGAKE designation, and what is its current status?
Japan’s Ministry of Health, Labour and Welfare introduced the SAKIGAKE designation system in 2015 to accelerate the regulatory review and approval of innovative therapies. Similar to the US FDA’s Breakthrough Therapy designation and the European Medicines Agency’s Priority Medicines program, SAKIGAKE is intended to expedite access to treatments for serious or life-threatening conditions.
The designation is granted to candidates demonstrating novel mechanisms of action supported by promising efficacy or safety data. Products receiving the designation benefit from a review period of approximately six months and prioritized consultation with the PMDA.
As of June 2026, four of the 25 regenerative medicine products approved in Japan had received SAKIGAKE designation. Three were developed by Japanese pharmaceutical companies, while one was sponsored by a global company.
During late 2025 and early 2026, four additional SAKIGAKE designations were awarded to sponsors based outside Japan.
How does Japan support orphan drug development?
Japan’s Ministry of Health, Labour and Welfare provides orphan drug designation for products targeting conditions affecting fewer than 50,000 people in Japan, where there is a high unmet medical need and no effective existing treatment.
Companies receiving this designation can benefit from:
- Priority regulatory review timelines of approximately nine months.
- A 10-year re-examination period.
- Flexibility for global development programs, without requiring a Japan-first or simultaneous submission in Japan.
Further information is available through the PMDA’s Overview of Orphan Drug Designation.
About Institute of Science Tokyo
The Institute of Science Tokyo (Science Tokyo) was established on October 1, 2024, following the merger of Tokyo Medical and Dental University (TMDU) and Tokyo Institute of Technology (Tokyo Tech). Its mission is to advance science and human well-being and create value for and with society.
About AGC Biologics
AGC Biologics is a global biopharmaceutical contract development and manufacturing organization (CDMO) committed to providing expert services and working closely with clients and partners.
The company provides development and manufacturing services for mammalian- and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors and genetically engineered cells.
Its global network extends across the United States, Europe and Asia, with facilities in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan.
AGC Biologics is part of AGC Inc.’s Life Science Business, which operates eight facilities focused on biopharmaceuticals, advanced therapies, small-molecule active pharmaceutical ingredients and agrochemicals.
For more information, visit www.agcbio.com.

